PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1189405
PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1189405
Asia-Pacific G-CSF/ PEG-G-CSF market is projected to register a substantial CAGR of 6.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Asia-Pacific G-CSF/PEG-G-CSF Market, By Indication (Neutropenia, Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Harmony Deficiency and Others), Dosage (Mono and Combination), Route Of Administration (Intravenous, Subcuetaneous), Packaging (Single Use Vials and Pre Filled Syringes), End User (Hospitals and Clinics, Research and Academic Institutes, Ambulatory Surgical Centers and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others), Country (China, Japan, India, Australia, New Zealand, Indonesia, Thailand, Vietnam, Singapore, Philippines, Malaysia, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.
Growing incidences of blood cancers and cancer diseases
Increasing cases of febrile neutropenia
Lupin
Gennova Biopharmaceuticals Limited
Reliance Life Sciences
Intas Pharmaceuticals Ltd.
BIOSIDUS
STADA Arzneimittel AG
USV Private Limited
Viatris Inc.
Biocon
Fresenius Kabi AG
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Amgen Inc.
Pfizer Inc.
Sandoz International GmbH
Apotex Inc.
Cadila Pharmaceuticals
Dr. Reddy's Laboratories Ltd.
Amneal Pharmaceuticals LLC.
Accord Healthcare
NAPP PHARMACEUTICALS LIMITED.
Intas Pharmaceuticals Ltd.
Mundipharma International
Teva Pharmaceutical Industries Ltd.
Spectrum Pharmaceuticals, Inc.
Kyowa Kirin Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.